Production and pre-clinical testing of MaxSi™ Graft synthetic bone graft substitutes

MaxSi™ Graft 合成骨移植替代品的生产和临床前测试

• 批准号: 102011
• 金额: $ 119.76万
• 依托单位: SIRAKOSS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102011
• 关键词: Production; pre; clinical; testing; MaxSi

SIRAKOSS Ltd have developed a novel bone graft substitute (BGS) that will revolutionise the treatment of bone defects and fusions. Developed to offer the surgeon an alternative to having to graft the patient’s own bone, which involves a second surgical procedure associated with graft site pain and increased healthcare costs, the SIRAKOSS synthetic implants are capable of regenerating bone in fractures and bone defects. Bone is the second most commonly transplanted tissue, next to blood, with over 2 million bone graft procedures performed worldwide every year. Biomedical Catalyst funding of £900,000 will allow SIRAKOSS to finalise development of their novel bone graft substitute and complete pre-clinical testing to support regulatory approval for clinical use in Europe.

SIRAKOSS有限公司开发了一种新型骨移植替代品(BGS)，它将彻底改变骨缺损和融合的治疗方法。SIRAKOSS合成植入物的开发目的是为外科医生提供一种替代方案，使其不必移植患者自己的骨，这涉及与移植部位疼痛和增加医疗成本相关的第二次手术程序，它能够在骨折和骨缺损中再生骨。骨是仅次于血液的第二种最常见的移植组织，全球每年进行的骨移植手术超过200万例。生物医学催化剂资助900,000 GB将使SIRAKOSS最终完成其新型骨移植替代品的开发，并完成临床前测试，以支持欧洲临床使用的监管批准。